# Prexasertib in Treating Pediatric Patients With Recurrent or Refractory Solid Tumors

> **NCT02808650** · PHASE1 · COMPLETED · sponsor: **Children's Oncology Group** · enrollment: 30 (actual)

## Conditions studied

- Childhood Solid Neoplasm
- Recurrent Malignant Solid Neoplasm
- Recurrent Primary Central Nervous System Neoplasm
- Refractory Malignant Solid Neoplasm
- Refractory Primary Central Nervous System Neoplasm

## Interventions

- **OTHER:** Laboratory Biomarker Analysis
- **OTHER:** Pharmacokinetic (PK) study
- **DRUG:** Prexasertib

## Key facts

- **NCT ID:** NCT02808650
- **Lead sponsor:** Children's Oncology Group
- **Sponsor class:** NETWORK
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-02-27
- **Primary completion:** 2019-12-31
- **Final completion:** 2021-03-31
- **Target enrollment:** 30 (ACTUAL)
- **Last updated:** 2023-12-20

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02808650

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02808650, "Prexasertib in Treating Pediatric Patients With Recurrent or Refractory Solid Tumors". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT02808650. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*